Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia
Status:
Recruiting
Trial end date:
2023-04-20
Target enrollment:
Participant gender:
Summary
Traditional management of community-acquired pneumonia (CAP) relies on the prompt
administration of antimicrobials that target the most common causative pathogens.
Retrospective analysis of observational clinical studies in CAP showed that the addition of
macrolides to standard antibiotic therapy conferred a significant survival benefit. The
proposed benefit of macrolides is coming from their anti-inflammatory mode of action. An RCT
that proves the attenuation of the high inflammatory burden of the host with CAP after
addition of clarithromycin in the treatment regimen is missing. This RCT is aiming to prove
that addition of oral clarithromycin to a β-lactam rapidly attenuates the high inflammatory
burden of the host in CAP.
Phase:
Phase 3
Details
Lead Sponsor:
Hellenic Institute for the Study of Sepsis
Treatments:
Ceftriaxone Clarithromycin Moxifloxacin Norgestimate, ethinyl estradiol drug combination